Challenging situations in primary percutaneous coronary intervention: clinical scenarios and main approaches

Abstract

Primary percutaneous coronary intervention (PCI) is one of the most effective treatment modalities for acute life-threatening diseases. Although successful PCI provides a direct positive effect on patient survival, failure may be associated with the disappearance of this benefit and, beyond that, worsening of the prognosis. Disparities in the coronary anatomy, the pathologic nature of the culprit lesion, and the underlying mechanisms of acute coronary syndrome can complicate PCI. An invasive cardiologist must be aware of these challenging situations and how best to manage them. This review aims to summarize troublesome scenarios such as no-reflow, large thrombotic lesions, ectasia-associated myocardial infarction, and spontaneous coronary artery dissection in primary PCI and to provide practical information on how to manage these situations.

Keywords

Acute myocardial infarction / thrombus / coronary artery ectasia / spontaneous coronary artery dissection

References

[1] Annibali G,Aranzulla TC,Maiellaro F."No-reflow" phenomenon: a contemporary review.J Clin Med2022;11:2233 PMCID:PMC9028464

[2] Kloner RA,Jennings RB.The "no-reflow" phenomenon after temporary coronary occlusion in the dog.J Clin Invest1974;54:1496-508 PMCID:PMC301706

[3] Study Group. The thrombolysis in myocardial infarction (TIMI) trial, phase I findings.N Engl J Med1985;312:932-6

[4] Carrick D,Maznyczka AM.Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction.Hypertension2018;72:720-30 PMCID:PMC6080885

[5] Mehta RH,Cox D.Primary Angioplasty in Myocardial Infarction (PAMI) InvestigatorsClinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention.J Am Coll Cardiol2003;42:1739-46

[6] Rezkalla SH,Abdalrahman IB.No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy.J Interv Cardiol2010;23:429-36

[7] Chesebro JH,Roberts R.Thrombolysis in myocardial infarction (TIMI) trial, phase i: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation1987;76:142-54

[8] Gibson CM,Murphy SA.Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.Circulation2000;101:125-30

[9] van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F; Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade.Circulation1998;97:2302-6

[10] Nijveldt R,Hirsch A.Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size.JACC Cardiovasc Imaging2009;2:1187-94

[11] de Waha S,Granger CB.Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.Eur Heart J2017;38:3502-10

[12] Galiuto L,Scarà A.AMICI InvestigatorsThe extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study.J Am Coll Cardiol2008;51:552-9

[13] Konijnenberg LSF,Duncker DJ.Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction.Cardiovasc Res2020;116:787-805 PMCID:PMC7061278

[14] Aggarwal P,Sinha SK,Khanra D.Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.Ann Cardiol Angeiol2021;70:136-42

[15] Nair Rajesh G,Madhavan S.Predictors and prognosis of no-reflow during primary percutaneous coronary intervention.Baylor Univ Med Cent Proc2019;32:30-3 PMCID:PMC6442883

[16] Bulluck H,Tan JW,Sezer M.Invasive assessment of the coronary microcirculation in peperfused ST-segment-elevation myocardial infarction patients: where do we stand?.Circ Cardiovasc Interv2017;10:e004373

[17] Feher A,Bagi Z.Prevention and treatment of no-reflow phenomenon by targeting the coronary microcirculation.Rev Cardiovasc Med2014;15:38-51

[18] Jaffe R,Strauss BH.Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.JACC Cardiovasc Interv2010;3:695-704

[19] Achkouty G,Sideris G.Microcatheter-facilitated primary angioplasty in ST-segment elevation myocardial infarction.Can J Cardiol2018;34:23-30

[20] Balaban Y,Bayramoğlu A,Kayışoğlu AH.Imaging behind occluded areas with an iatrogenic perforated balloon: a safe, practical, and simple new method of visualizing the distal lumen in total occlusion.J Interv Cardiol2017;30:544-9

[21] Akpek M,Sarli B.Acute effects of intracoronary tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention.Angiology2015;66:560-7

[22] Correction to: 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC).Eur Heart J2024;45:1145

[23] Aksu T,Colak A.Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study.BMC Cardiovasc Disord2015;15:10 PMCID:PMC4353473

[24] Afshar E, Samimisedeh P, Tayebi A, Shafiabadi Hassani N, Rastad H, Yazdani S. Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study.Ther Adv Cardiovasc Dis2023;17:17539447231154654 PMCID:PMC10071100

[25] Navarese EP,Kandzari DE.Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study.Catheter Cardiovasc Interv2021;97:602-11

[26] Forman MB,Jackson EK.Treating acute "no-reflow" with intracoronary adenosine in 4 patients during percutaneous coronary intervention.Tex Heart Inst J2008;35:439-46 PMCID:PMC2607097

[27] Fu XH,Gu XS.Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction.Chin Med J2007;120:1226-31.Available from: https://journals.lww.com/cmj/fulltext/2007/07020/Effect_of_intracoronary_administration_of.4.aspx. [Last accessed on 20 Dec 2024]

[28] Huang RI,Walinsky P.Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention.Catheter Cardiovasc Interv2006;68:671-6

[29] Kobatake R,Fujiwara Y.Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.Heart Vessels2011;26:379-84

[30] Tesic MB,Vukcevic V.The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction.Herz2010;35:114-8

[31] Wang L,Gu Y.Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials.Biomed Res Int2015;2015:382086 PMCID:PMC4609355

[32] Niu X,Bai M,Sun S.Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.BMC Cardiovasc Disord2018;18:3 PMCID:PMC5763527

[33] Darwish A,Abdelsamie M,Gouda M.Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study.Ann Saudi Med2022;42:75-82 PMCID:PMC8981999

[34] Maluenda G,Delhaye C.Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes.J Interv Cardiol2010;23:109-13

[35] Movahed MR.Successful distal administration of high doses of adenosine and nicardipine using export catheter for treatment of resistant no-reflow in a vein graft.Am J Cardiovasc Dis2022;12:53-5 PMCID:PMC8918739

[36] Movahed MR.Successful distal administration of high doses of adenosine has been reported using export or other catheters since 2008.Cardiovasc Revasc Med2023;53:75

[37] Cetin M,Güven Cetin Z,Gulkan B.A practical method for no-reflow treatment.Case Rep Cardiol2016;2016:9596123 PMCID:PMC4766333

[38] Bashtawi Y.Therapeutic hypothermia in STEMI.Cardiovasc Revasc Med2021;29:77-84

[39] Keeble TR,Noc M.Effect of intravascular cooling on microvascular obstruction (MVO) in conscious patients with ST-elevation myocardial infarction undergoing primary PCI: results from the COOL AMI EU pilot study.Cardiovasc Revasc Med2019;20:799-804

[40] Mukherjee P.Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a single-center cross-sectional study.Ann Card Anaesth2019;22:347-52 PMCID:PMC6813695

[41] Thygesen K,Jaffe AS.Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial InfarctionFourth universal definition of myocardial infarction (2018).Circulation2018;138:e618-51

[42] Sianos G,Daemen J.Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden.J Am Coll Cardiol2007;50:573-83

[43] Kumar V,Kumar T.Large intracoronary thrombus and its management during primary PCI.Indian Heart J2020;72:508-16 PMCID:PMC7772595

[44] Gibson CM,Murphy SA.TIMI Study GroupCombination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.Circulation2001;103:2550-4

[45] Jolly SS,Yusuf S.TOTAL InvestigatorsRandomized trial of primary PCI with or without routine manual thrombectomy.N Engl J Med2015;372:1389-98 PMCID:PMC4995102

[46] Huang YX,Chen Y.AngioJet rheolytic thrombectomy in patients with thrombolysis in myocardial infarction thrombus grade 5: an observational study.Sci Rep2022;12:5462 PMCID:PMC8971501

[47] Tashtish N,Dong T.Routine use of the "penumbra" thrombectomy device in myocardial infarction: a real-world experience-ROPUST study.J Interv Cardiol2022;2022:5692964

[48] Pradhan A,Vishwakarma P.Deferred stenting for heavy thrombus burden during percutaneous coronary intervention for ST-elevation MI.Eur Cardiol2021;16:e08 PMCID:PMC8054343

[49] Custodio-Sánchez P,Peña-Duque MA.Deferred versus immediate stenting in patients with ST - segment elevation myocardial infarction and residual large thrombus burden reclassified in the culprit lesion.Arch Cardiol Mex2018;88:432-40

[50] Araiza-Garaygordobil D,González-Gutiérrez JC.Coronary artery ectasia in ST-elevation myocardial infarction: prevalence and prognostic implications.Coron Artery Dis2022;33:671-3

[51] Matta AG,Nader V,Carrie D.Coronary artery aneurysm: a review.World J Cardiol2021;13:446-55 PMCID:PMC8462041

[52] Carrick D,McEntegart M.A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI).J Am Coll Cardiol2014;63:2088-98 PMCID:PMC4029071

[53] Yokokawa T,Kaneko H,Kijima M.Lone aspiration thrombectomy without stenting for a patient with ST-segment elevation myocardial infarction associated with coronary ectasia.Cardiovasc Interv Ther2014;29:339-43

[54] Kawsara A,Alqahtani F,Rihal CS.Management of coronary artery aneurysms.JACC Cardiovasc Interv2018;11:1211-23

[55] Núñez-Gil IJ,Feltes G.Coronary aneurysms in the acute patient: incidence, characterization and long-term management results.Cardiovasc Revasc Med2018;19:589-96

[56] Marschall A,Alfonso F.Double gender bias in spontaneous coronary artery dissection.Rev Esp Cardiol (Engl Ed)2024;77:276

[57] Di Fusco SA,Zilio F.Spontaneous coronary artery dissection: overview of pathophysiology.Trends Cardiovasc Med2022;32:92-100

[58] Saw J,Sedlak T.Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes.Circ Cardiovasc Interv2014;7:645-55

[59] Kidess GG,Harmouch KM,Chadi Alraies M.Spontaneous coronary artery dissection: a review of medical management approaches.Curr Probl Cardiol2024;49:102560

[60] Kim ESH.Spontaneous coronary-artery dissection.N Engl J Med2020;383:2358-70

[61] Mehmedbegović Z,Čanković M.Invasive imaging modalities in a spontaneous coronary artery dissection: when "believing is seeing".Front Cardiovasc Med2023;10:1270259

[62] Saw J,Humphries K.Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes.Eur Heart J2019;40:1188-97 PMCID:PMC6462308

[63] Cerrato E,Quadri G.DISCO CollaboratorsAntiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.Eur Heart J2021;42:3161-71

[64] Offen S,Saw J.Spontaneous coronary artery dissection (SCAD): a contemporary review.Clin Cardiol2024;47:e24236 PMCID:PMC11165169

[65] Saw J,Aymong E.Canadian spontaneous coronary artery dissection cohort study: 3-year outcomes.J Am Coll Cardiol2022;80:1585-97

[66] Main A.Percutaneous coronary intervention for the treatment of spontaneous coronary artery dissection.Interv Cardiol Clin2019;8:199-208

[67] Benenati S,Macaya F.DISCO CollaboratorsImpaired culprit-vessel flow affects percutaneous coronary intervention outcomes in spontaneous coronary artery dissections.Am J Cardiol2024;219:35-7